Revvity

Management concluded that the applied-markets and diagnostics businesses had diverging capital-allocation priorities and investor bases. By selling the applied segment for $2.45 billion and rebranding as Revvity, the remaining entity could reinvest proceeds entirely into life-science tools without cross-subsidizing slower-growth industrial divisions. The result is a streamlined acquirer focused on lab automation, immunodiagnostics, and preclinical software.

Deal flow originates primarily through relationships with venture-backed life-science startups and academic spinouts developed over PerkinElmer's multi-decade instrument-installed base. Revvity typically acquires companies whose assays or software complement its existing automation platforms, often identifying targets after they achieve regulatory clearance but before they build independent commercial scale.

Revvity is a publicly traded corporation (NYSE: RVTY) with no family-office structure. It is an operating company that manufactures and sells scientific instruments, reagents, and software. Institutional investors own the vast majority of its equity; no single family controls the board or investment decisions.

Roughly 85% of revenue ties directly to pharmaceutical and biotech R&D budgets, making Revvity more cyclically exposed than diversified tools peers. During pharma pipeline contractions, consumables pull-through and instrument orders have historically declined; conversely, strong NME approval cycles drive growth in its high-content screening and automation divisions.

No. Revvity does not commit capital to external venture or private equity funds. Corporate venture activities are conducted through discrete technology licensing agreements and occasional minority equity stakes in firms whose platforms it may eventually acquire.

The $5.25 billion BioLegend acquisition, closed in late 2021 while still operating as PerkinElmer, added a high-growth, high-margin antibody and reagent franchise with a direct channel to immunology researchers. Post-rebrand, BioLegend remains Revvity's flagship protein-biology platform, and the management team that built it was retained to drive further organic expansion in multiplexed proteomics.

Revvity explicitly avoids applied markets — food safety testing, environmental analysis, and industrial quality control — which was the entire segment sold to New Mountain Capital. It also does not manufacture therapeutic drugs or provide clinical care, staying strictly on the tools-and-software side of life sciences.